Tuberculosis and Respiratory Diseases最新文献

{"title":"Adherence to Pharmacological Management Guidelines for Stable Chronic Obstructive Lung Disease.","authors":"Sang Min Han, Hyo Seon Kim, Seung Yong Park, Heung Bum Lee, Young Bum Park, Chin Kook Rhee, Youlim Kim, Seoung Ju Park","doi":"10.4046/trd.2024.0130","DOIUrl":"10.4046/trd.2024.0130","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated adherence to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Korean guidelines in the prescription patterns of respiratory specialists for stable chronic obstructive pulmonary disease (COPD) management.</p><p><strong>Methods: </strong>Data were collected on medications from 2011 to 2022 using the Korea COPD Subtype Study (KOCOSS) cohort. Patients were divided into two groups: those registered before and after 2019, and we analyzed the percentage of patients meeting the recommended treatment criteria established by each guideline.</p><p><strong>Results: </strong>Among 3,477 patients, 85.6% received pharmacological therapy, and 81.6% utilized inhaled medications. Compared to patients enrolled before 2019, there was an increase in inhaler prescriptions among those registered after 2019 (79.7% vs. 86.7%), with dual bronchodilators being the predominant therapy prescribed. Of the patients receiving treatment, 56.9% adhered to the Korean 2018 guideline. Compliance with the GOLD 2019 and GOLD 2023 guidelines was observed in 31.3% and 28.0% of cases, respectively. When analyzing inhaler prescription patterns according to both subgroups and considering the Korean 2018, GOLD 2019, and GOLD 2023 guidelines concurrently, the adherence rates were as follows: (56.6%, 37.8%, 24.0%) and (57.7%, 14.0%, 38.6%).</p><p><strong>Conclusion: </strong>Adherence rates were higher for the Korean guideline compared to the GOLD recommendations. Furthermore, alignment with both the Korean 2018 and GOLD 2023 guidelines increased among patients enrolled after 2019, compared to those registered earlier. These findings suggest that physicians are modifying their therapeutic strategies to align with both domestic and recent international guidelines.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"310-321"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Chronic Obstructive Pulmonary Disease in Vietnam during the COVID-19 Period: Current Situation and Challenges.","authors":"Thuy Thanh Phan, Giap Van Vu, Chau Quy Ngo","doi":"10.4046/trd.2024.0140","DOIUrl":"10.4046/trd.2024.0140","url":null,"abstract":"<p><strong>Background: </strong>To assess the alterations in exacerbation rates, other clinical outcomes, and to identify persistent challenges in the management of chronic obstructive pulmonary disease (COPD) in Vietnamese COPD management units (CMUs).</p><p><strong>Methods: </strong>A multi-center, prospective cohort study was conducted on COPD within the CMUs of three study sites. The primary endpoint was exacerbation frequency. Data on demographic and clinical characteristics were collected at the initiation of the study. Participants were followed for 12 to 15 months after enrollment.</p><p><strong>Results: </strong>Throughout the follow-up period, a decrease was noted in the prevalence of patients requiring hospitalization (from 42.3% to 34.4%) and intensive care unit/emergency department admissions (from 5.7% to 0.6%). The annual rates of exacerbation and hospitalization were 0.75±0.89 and 0.56±0.70, respectively. Factors such as symptom severity, degree of airflow obstruction, and body mass index were associated with increased exacerbation frequency and elevated annual exacerbation rates. Our findings underscore the complexities and obstacles encountered in managing COPD during the coronavirus disease 2019 (COVID-19) pandemic, including the rise in smoking prevalence, inadequate testing rates, and non-compliance with established treatment guidelines.</p><p><strong>Conclusion: </strong>Our study elucidates the challenges and difficulties in managing COPD amidst the COVID-19 pandemic, highlighting issues such as increased smoking rates, insufficient testing, and deviations from established therapeutic guidelines. These insights lay the groundwork for future intervention strategies and policy enhancements.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"322-333"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update in Association between Lung Cancer and Air Pollution.","authors":"Jiye Yoo, Yongchan Lee, Youngil Park, Jongin Lee, Joon Young Choi, Heekwan Lee, Jeong Uk Lim","doi":"10.4046/trd.2024.0092","DOIUrl":"10.4046/trd.2024.0092","url":null,"abstract":"<p><p>A significant portion of newly diagnosed lung cancer cases occurs in populations exposed to air pollution. The World Health Organization has identified air pollution as a human carcinogen, prompting many countries to implement monitoring systems for ambient particulate matter (PM). PM is composed of a complex mixture of organic and inorganic particles, both solid and liquid, that are found in the air. Given the carcinogenic properties of PM and the high prevalence of lung cancer among exposed populations, exploring their connection and clinical implications is critical for effectively preventing lung cancer in this group. This review explores the relationship between ambient PM and lung cancer. Epidemiological studies have demonstrated a dose-response relationship between PM exposure and lung cancer risk. PM exposure induces oxidative stress, disrupts the body's redox balance, and causes DNA damage, which is a crucial factor in cancer development. Recent findings on the strong correlation between ambient PM and adenocarcinoma highlight the importance of understanding the specific molecular and pathological mechanisms underlying pollution-related lung cancer. In addition to efforts to control emission sources at the international level, a more individualized approach is essential for preventing PM-related lung cancer.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"228-236"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Severe Asthma Registry (ISAR): 2017-2024 Status and Progress Update.","authors":"Désirée Larenas-Linnemann, Chin Kook Rhee, Alan Altraja, John Busby, Trung N Tran, Eileen Wang, Todor A Popov, Patrick D Mitchell, Paul E Pfeffer, Roy Alton Pleasants, Rohit Katial, Mariko Siyue Koh, Arnaud Bourdin, Florence Schleich, Jorge Máspero, Mark Hew, Matthew J Peters, David J Jackson, George C Christoff, Luis Perez-de-Llano, Ivan Cherrez-Ojeda, João A Fonseca, Richard W Costello, Carlos A Torres-Duque, Piotr Kuna, Andrew N Menzies-Gow, Neda Stjepanovic, Peter G Gibson, Paulo Márcio Pitrez, Celine Bergeron, Celeste M Porsbjerg, Camille Taillé, Christian Taube, Nikolaos G Papadopoulos, Andriana I Papaioannou, Sundeep Salvi, Giorgio Walter Canonica, Enrico Heffler, Takashi Iwanaga, Mona S Al-Ahmad, Sverre Lehmann, Riyad Al-Lehebi, Borja G Cosio, Diahn-Warng Perng, Bassam Mahboub, Liam G Heaney, Pujan H Patel, Njira Lugogo, Michael E Wechsler, Lakmini Bulathsinhala, Victoria Carter, Kirsty Fletton, David L Neil, Ghislaine Scelo, David B Price","doi":"10.4046/trd.2024.0198","DOIUrl":"10.4046/trd.2024.0198","url":null,"abstract":"<p><p>The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"193-215"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Connective Tissue Disease Associated Interstitial Lung Disease.","authors":"Ju Hyun Oh, Jae Ha Lee, Sung Jun Chung, Young Seok Lee, Tae-Hyeong Kim, Tae-Jung Kim, Joo Hun Park","doi":"10.4046/trd.2024.0148","DOIUrl":"10.4046/trd.2024.0148","url":null,"abstract":"<p><p>Connective tissue disease (CTD), comprising a range of autoimmune disorders, is often accompanied by lung involvement, which can lead to life-threatening complications. The primary types of CTDs that manifest as interstitial lung disease (ILD) include rheumatoid arthritis, systemic sclerosis, Sjögren's syndrome, mixed CTD, idiopathic inflammatory myopathies, and systemic lupus erythematosus. CTD-ILD presents a significant challenge in clinical diagnosis and management due to its heterogeneous nature and variable prognosis. Early diagnosis through clinical, serological, and radiographic assessments is crucial for distinguishing CTD-ILD from idiopathic forms and for implementing appropriate therapeutic strategies. Hence, we have reviewed the multiple clinical manifestations and diagnostic approaches for each type of CTD-ILD, acknowledging the diversity and complexity of the disease. The importance of a multidisciplinary approach in optimizing the management of CTD-ILD is emphasized by recent therapeutic advancements, which include immunosuppressive agents, antifibrotic therapies, and newer biological agents targeting specific pathways involved in the pathogenesis. Therapeutic strategies should be customized according to the type of CTD, the extent of lung involvement, and the presence of extrapulmonary manifestations. Additionally, we aimed to provide clinical guidance, including therapeutic recommendations, for the effective management of CTD-ILD, based on patient, intervention, comparison, outcome (PICO) analysis.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"247-263"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric Analysis of Nontuberculous Mycobacteria Research in South Korea.","authors":"Geunin Lee, Young Ae Kang, Youngmok Park","doi":"10.4046/trd.2024.0158","DOIUrl":"10.4046/trd.2024.0158","url":null,"abstract":"<p><strong>Background: </strong>Current research on nontuberculous mycobacteria (NTM) is multidisciplinary, necessitating proper organization to obtain comprehensive insight. Therefore, a bibliometric analysis was performed to identify NTM research characteristics in South Korea.</p><p><strong>Methods: </strong>The Web of Science was searched for NTM articles authored by Koreans at Korean institutions until March 2023. We collected data on authors, publication year, article type, study design, research area, citations, research institutes, and funding sources.</p><p><strong>Results: </strong>Of the 28,092 articles on NTM, Koreans authored 868. After excluding 167 unrelated studies, 701 relevant articles were analyzed. The first study was from 1992, with publication rates markedly increasing from 2004 onward. Basic research constituted 41.3% (n=290) of the papers, whereas clinical research represented 44.7% (n=313). Basic research consisted mostly of biochemistry studies (n=73, 10.4%), whereas clinical research primarily involved retrospective studies (n=118, 16.8%). Fifty-four institutions participated in NTM research, with the top five contributing to 71% (n=498) of the publications. The National Research Foundation of Korea was the most significant funding source, supporting 181 studies (32.5% of funded articles). Citation analysis revealed a median citation count of 10 (interquartile range, 3 to 13), with clinical research dominating the top-cited articles and a rise in publications in high-impact journals over time.</p><p><strong>Conclusion: </strong>The quality and quantity of NTM research in South Korea has improved. However, it is concentrated in a few institutions and is largely funded by a few sources. Future research should use more diverse funding sources, be conducted in more institutions, and prioritize prospective study designs to enhance the understanding and treatment of NTM.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"353-360"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Request for Study Design Modification in Examining Nutritional Intake and Muscle Strength in Individuals with Airflow Limitation.","authors":"Ming-Che Chang, Chii-Lan Lin, Fong-Fong Tsai, Hwei-Mei Tai, Chih-Wei Kuo, Hon-Kwong Ma, Chih-Chung Shiao","doi":"10.4046/trd.2024.0171","DOIUrl":"10.4046/trd.2024.0171","url":null,"abstract":"","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"408-410"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Anticancer Effects of Histone Deacetylase Inhibitors CG-745 and Suberoylanilide Hydroxamic Acid in Non-small Cell Lung Cancer.","authors":"Hyo Jin Kim, Ui Ri An, Han Jee Yoon, Hyun Lim, Ki Eun Hwang, Young Suk Kim, Hak Ryul Kim","doi":"10.4046/trd.2024.0090","DOIUrl":"10.4046/trd.2024.0090","url":null,"abstract":"<p><strong>Background: </strong>Histone deacetylase (HDAC) inhibition offers potential anticancer effects across diverse cancers due to HDAC&apos;s significant role in cancer development and progression. Consequently, we demonstrated the therapeutic efficacy of the novel HDAC inhibitor, CG-745, in comparison with existing inhibitors such as suberoylanilide hydroxamic acid (SAHA) in non-small cell lung cancer (NSCLC) cells.</p><p><strong>Methods: </strong>CG-745&apos;s effect on apoptosis and reactive oxygen species (ROS)-dependent mitochondrial dysfunction was investigated using annexin V assay, MitoSoX, and Western blot in human A549 and H460 cells. Additionally, HDAC expression was analyzed through real-time polymerase chain reaction. We also evaluated the inhibitory effect of CG-745 on epithelial-mesenchymal transition (EMT) induced by transforming growth factor β1 (TGF-β1) via Western blot, scratch analysis, and matrigel invasion analysis.</p><p><strong>Results: </strong>Compared to SAHA, CG-745 inhibited cell viability and mRNA expression of HDACs such as HDAC1, HDAC2, HDAC3, and HDAC8. It also induced apoptosis, ROS, and mitochondrial dysfunction in a concentration-dependent manner. CG-745 reversed EMT triggered by TGF-β1 in A549 and H460 cells, and curtailed the migration and invasion enhanced by TGF-β1. CG-745 has demonstrably inhibited EMT and induced apoptosis in NSCLC cells.</p><p><strong>Conclusion: </strong>CG-745 may represent a novel therapeutic strategy for NSCLC treatment.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"342-352"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maximal forced inspiratory flow dynamics and acute exacerbation in COPD patients with exacerbation history.","authors":"Heemoon Park, Jung-Kyu Lee, Eun Young Heo, Deog Kyeom Kim, Hyun Woo Lee","doi":"10.4046/trd.2024.0156","DOIUrl":"https://doi.org/10.4046/trd.2024.0156","url":null,"abstract":"<p><strong>Background: </strong>Chronic Obstructive Pulmonary Disease (COPD) is a significant global health burden characterized by progressive airflow obstruction and frequent exacerbations. Traditionally, COPD severity has been assessed using expiratory flow measurements like FEV1. However, the role of inspiratory flow, specifically maximal forced inspiratory flow (FIFmax), in predicting exacerbation risk is gaining attention.</p><p><strong>Methods: </strong>This retrospective cohort study evaluated COPD patients with a history of exacerbations, receiving inhaled therapy. The eligible patients were followed up for 3 years with spirometric assessments. Patients were categorized into quartiles based on the annual change in FIFmax, from the greatest decrease (Q1) to the greatest increase (Q4). Primary outcome was acute exacerbation, stratified by severity as moderate-to-severe and severe exacerbation.</p><p><strong>Results: </strong>A total of 180 patients were followed up for 3 years. While a greater increase in FIFmax was linearly associated with lower rates of both moderate-to-severe and severe exacerbations (P-value for trend <0.001 for both), time-to-event analysis revealed no significant association between FIFmax changes and moderate-to-severe exacerbations. In contrast, a significant association was observed with severe exacerbations (Log-Rank P-value=0.005). Even after adjusting for confounders, FIFmax remained an independent predictor of severe exacerbations (Q3: hazard ratio=0.506 [95% confidence interval=0.306-0.836], P-value=0.008; Q4: hazard ratio=0.491 [95% confidence interval=0.291-0.830], P-value=0.008).</p><p><strong>Conclusions: </strong>Changes in FIFmax were not significantly associated with moderate-to-severe exacerbations but were related with a reduced risk of severe exacerbations in COPD patients receiving inhaled therapy. These findings suggest that FIFmax may serve as a valuable prognostic marker for severe exacerbations in high-risk COPD patients.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Role of Molecular Testing in the Management of Non-Metastatic Non-Small Cell Lung Cancer.","authors":"Hidenori Kage","doi":"10.4046/trd.2024.0159","DOIUrl":"https://doi.org/10.4046/trd.2024.0159","url":null,"abstract":"<p><p>Advances in targeted therapies and immune checkpoint inhibitors have significantly enhanced survival rates for patients with metastatic non-small cell lung cancer (NSCLC). For non-metastatic NSCLC, addition of immune checkpoint inhibitors post-chemoradiotherapy has improved outcomes in stage III disease and during the perioperative phase for stages IB-IIIA. Recently, adjuvant osimertinib and alectinib therapy have demonstrated improved survival for patients with EGFR or ALK alterations, respectively, and they have been established as standard therapies. Furthermore, osimertinib has proven effective when administered following chemoradiotherapy in stage III NSCLC. These studies highlight the necessity to assess EGFR and ALK status to guide treatment decisions for almost all NSCLC patients, regardless of whether they will undergo curative surgery, chemoradiotherapy, or as palliative chemotherapy. This review summarizes recent trials on perioperative and post-chemoradiation therapy and argues that molecular testing is required for non-metastatic NSCLC to improve patient outcomes.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}